Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Un Kwon-Casado, Geert Nygaard, Thomas Taapken, Uwe Staub, Yitzhak Peterburg


Fluidigm has promoted Un Kwon-Casado to the position of vice president of corporate development, the company said.
Kwon-Casado has served as director of strategic marketing at Fluidigm since October 2009. Prior to that she was vice president of healthcare equity research for Pacific Growth Equities.

Epigenomics disclosed last week that company CEO Geert Nygaard left the firm as of Sept. 30, and that Thomas Taapken has been appointed as sole member of the company's executive board, effective Oct. 1.

Taapken previously served as chief financial officer at Epigenomics, a position he held since April 2011. He joined Epigenomics from Biotie Therapies in Finland, where he also served as CFO. He was appointed to that position in 2008, following a merger between Biotie Therapies and Elbion, where Taapken had been CFO since 2005. He has also held positions as an investment partner at Deutsche Venture Capital and Burrill & Company. Taapken also worked several years at Sanofi-Aventis.

Epigenomics also disclosed that it has promoted Uwe Staub, former senior vice president of research and development, to the position of chief operating officer.

Rosetta Genomics has nominated Yitzhak Peterburg to serve on the company's board of directors and has called a shareholder meeting to approve the appointment. If approved, he will be the seventh member of Rosetta Genomics' board.

Peterburg formerly was senior vice president and head of Global Branded Products at Teva Pharmaceuticals, where he currently is a board member. He also was general manager at Clalit Health Services, an Israeli non-government, non-profit comprehensive health services organization, and he was CEO of Soroka University Medical Center.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.